Sensus Healthcare (NASDAQ:SRTS) Releases Quarterly Earnings Results, Misses Expectations By $0.04 EPS

Key Points

• Sensus Healthcare reported quarterly EPS of -$0.16, missing analyst expectations by $0.04, on revenue of $3.39 million, well below the $5.32 million consensus estimate.
• Management said newly effective CPT reimbursement codes could materially improve economics starting in 2026, with early claim processing feedback already boosting physician interest and pipeline growth.
• The quarter was hurt by the absence of sales to its historically largest customer, but the company is pushing recurring revenue through Sensus Link, Fair Deal/rental sites, and new financing initiatives as it targets stronger second-half results and profitability.

Sensus Healthcare (NASDAQ:SRTS - Get Free Report) posted its quarterly earnings data on Thursday. The company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.04), Zacks reports. The firm had revenue of $3.39 million for the quarter, compared to analyst estimates of $5.32 million. Sensus Healthcare had a negative return on equity of 15.11% and a negative net margin of 28.09%.

Here are the key takeaways from Sensus Healthcare's conference call:

• Sensus says new dedicated CPT codes effective Jan 1, 2026 materially improve reimbursement — including about a 300% increase in the per‑fraction delivery code — and early EOBs show payers are processing claims, which management says is driving stronger physician interest and pipeline growth.
• Q1 revenue was $3.4 million versus $8.3 million a year ago primarily because there were no sales to the company's historically largest customer; adjusted EBITDA was negative $4.2 million and net loss was $2.6 million, though management notes underlying growth when excluding that customer.
• Management is prioritizing recurring revenue through the Sensus Link software and the Fair Deal/rental program (18 active Fair Deal sites, 9 pending), and highlighted a reimbursable weekly radiation physics code (~$93.85/week) that can be monetized and shared with customers via Sensus Link.
• Commercial expansion initiatives — 14 systems shipped in Q1 (10 direct, 4 Fair Deal/rental), ~70% purchases of systems in the quarter, the launch of Sensus Healthcare Financial Services, and a stronger conference-driven pipeline — underpin management's expectation of higher Q2/H2 revenue and a path to full‑year profitability.

Sensus Healthcare Stock Down 25.1%

SRTS stock traded down $1.03 during midday trading on Friday, reaching $3.08. The company's stock had a trading volume of 665,134 shares, compared to its average volume of 84,977. Sensus Healthcare has a 52 week low of $2.82 and a 52 week high of $5.92. The stock has a market cap of $50.70 million, a PE ratio of -6.55 and a beta of 1.19. The business's 50-day simple moving average is $4.14 and its 200-day simple moving average is $4.16.

Analyst Ratings Changes

Several analysts have recently weighed in on the stock. Wall Street Zen lowered shares of Sensus Healthcare from a "hold" rating to a "sell" rating in a report on Saturday, February 14th. Maxim Group decreased their price target on shares of Sensus Healthcare from $8.00 to $6.00 and set a "buy" rating on the stock in a research note on Tuesday, February 17th. Citigroup reissued a "buy" rating on shares of Sensus Healthcare in a research note on Friday. Alliance Global Partners assumed coverage on shares of Sensus Healthcare in a research note on Friday, March 6th. They set a "buy" rating and a $7.50 price target on the stock. Finally, Weiss Ratings reissued a "sell (d)" rating on shares of Sensus Healthcare in a research note on Tuesday, April 21st. Five investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $6.88.

Hedge Funds Weigh In On Sensus Healthcare

A number of hedge funds and other institutional investors have recently bought and sold shares of SRTS. Geode Capital Management LLC boosted its position in shares of Sensus Healthcare by 2.5% during the second quarter. Geode Capital Management LLC now owns 153,917 shares of the company's stock worth $730,000 after purchasing an additional 3,766 shares in the last quarter. Jane Street Group LLC bought a new position in shares of Sensus Healthcare during the fourth quarter worth $79,000. State Street Corp boosted its position in shares of Sensus Healthcare by 5.2% during the fourth quarter. State Street Corp now owns 69,252 shares of the company's stock worth $276,000 after purchasing an additional 3,400 shares in the last quarter. Ingalls & Snyder LLC bought a new position in shares of Sensus Healthcare during the fourth quarter worth $219,000. Finally, Greenline Wealth Management LLC bought a new position in shares of Sensus Healthcare during the fourth quarter worth $513,000. 25.30% of the stock is owned by institutional investors.

About Sensus Healthcare

Sensus Healthcare, Inc is a medical technology company specializing in the development, manufacture and commercialization of superficial radiation therapy (SRT) systems. The company's SRT devices utilize low-energy X-rays to treat a range of dermatological and oncological conditions, most notably non-melanoma skin cancers such as basal cell carcinoma and squamous cell carcinoma, as well as benign lesions including keloids. By delivering targeted radiation to superficial tissue layers, Sensus Healthcare's systems aim to provide an alternative to surgical excision or systemic therapies, offering clinicians a non-invasive treatment option for eligible patients.

The company's flagship products include the SRT-100™ and SRT-100+™ platforms, which feature handheld applicators, adjustable energy settings and integrated safety controls.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.